We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
+39.29%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$646M
AUM Growth
+$3.57M
Cap. Flow
-$92.1M
Cap. Flow %
-14.26%
Top 10 Hldgs %
76.2%
Holding
43
New
2
Increased
4
Reduced
2
Closed
4

Top Buys

Rank Stock Value
1
NKTX icon
Nkarta
NKTX
+$9.36M
2
JSPR icon
Jasper Therapeutics
JSPR
+$9.33M
3
MLYS icon
Mineralys Therapeutics
MLYS
+$6.86M
4
ADVM
Adverum Biotechnologies
ADVM
+$4.44M
5
VTVT icon
vTv Therapeutics
VTVT
+$2.11M

Top Sells

Rank Stock Value
1
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$115M
2
JANX icon
Janux Therapeutics
JANX
+$3.92M
3
PEPG icon
PepGen
PEPG
+$2.97M
4
RAIN
Rain Oncology Inc. Common Stock
RAIN
+$2.44M
5
ACLX
Arcellx
ACLX
+$431K

Sector Composition

Rank Sector Weight
1 Healthcare 99.72%
2 Financials 0.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRRK icon
1
Scholar Rock
SRRK
$5.93B
$121M 18.65%
6,788,609
– –
CRGX
2
DELISTED
CARGO Therapeutics
CRGX
$92M 14.23%
4,121,689
– –
MLYS icon
3
Mineralys Therapeutics
MLYS
$2.45B
$65.5M 10.14%
5,074,916
+555,555
+12% +$6.86M
NGNE icon
4
Neurogene
NGNE
$682M
$64.5M 9.98%
1,267,790
– –
NKTX icon
5
Nkarta
NKTX
$167M
$40.7M 6.3%
3,768,035
+900,000
+31% +$9.36M
ACLX
6
DELISTED
Arcellx
ACLX
$31.6M 4.88%
453,641
-6,800
-1% -$431K
LENZ
7
LENZ Therapeutics
LENZ
$181M
$27M 4.17%
1,208,473
– –
LYRA
8
DELISTED
LYRA THERAPEUTICS INC
LYRA
$17.3M 2.68%
55,605
– –
SLRN
9
DELISTED
ACELYRIN
SLRN
$17M 2.63%
2,523,022
– –
AVDL
10
DELISTED
Avadel Pharmaceuticals
AVDL
$16.3M 2.53%
967,527
– –
JSPR icon
11
Jasper Therapeutics
JSPR
$22.7M
$15.4M 2.38%
+525,000
New +$9.33M
ZYME icon
12
Zymeworks
ZYME
$1.71B
$15.3M 2.37%
1,458,875
– –
HLVX
13
DELISTED
HilleVax
HLVX
$13.3M 2.06%
799,274
– –
ABVX
14
Abivax
ABVX
$11.2B
$12.2M 1.88%
850,000
– –
INZY
15
DELISTED
Inozyme Pharma
INZY
$12M 1.85%
1,562,500
– –
SYRS
16
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$9.56M 1.48%
1,786,427
– –
STRO icon
17
Sutro Biopharma
STRO
$392M
$9.47M 1.46%
167,558
– –
RYTM icon
18
Rhythm Pharmaceuticals
RYTM
$7.37B
$7.48M 1.16%
172,647
– –
GOSS icon
19
Gossamer Bio
GOSS
$93M
$7.23M 1.12%
6,130,268
– –
JANX icon
20
Janux Therapeutics
JANX
$947M
$6.78M 1.05%
180,207
-180,207
-50% -$3.92M
IOBT
21
DELISTED
IO Biotech
IOBT
$6.3M 0.97%
3,640,015
– –
VRNA
22
DELISTED
Verona Pharma
VRNA
$5.59M 0.87%
347,500
– –
TNGX icon
23
Tango Therapeutics
TNGX
$4.34B
$5M 0.77%
630,000
– –
VTVT icon
24
vTv Therapeutics
VTVT
$121M
$4.87M 0.75%
206,784
+165,896
+406% +$2.11M
IMTX icon
25
Immatics
IMTX
$1.26B
$4.16M 0.64%
396,000
– –
1
2

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
GSIS
Global Strategic Investment Solutions Scottsdale, Arizona $1.03B AUM 16.75% 1-Year Est. Return
RIM
RW Investment Management Eagle, Idaho $1.03B AUM
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return

Samsara BioCapital's Q1 2024 Portfolio in Review

As of Q1 2024, Samsara BioCapital held 43 positions worth $646M, up 0.56% from $643M the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Samsara BioCapital withdrew a net $92.1M in Q1 2024, closing 4 positions and reducing 2 holdings. Its most notable exit was RayzeBio, Inc. Common Stock, an estimated $115M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

Against the trend, Samsara BioCapital opened a new position in Jasper Therapeutics worth $15.4M.

  • Samsara BioCapital's largest Q1 2024 buy was Jasper Therapeutics: 525,000 shares worth $15.4M.
  • Samsara BioCapital added most to Nkarta in Q1 2024, an estimated $9.36M increase.
  • Samsara BioCapital's biggest Q1 2024 reduction was Janux Therapeutics, cutting an estimated $3.92M.
  • Samsara BioCapital fully exited RayzeBio, Inc. Common Stock in Q1 2024, selling an estimated $115M.
  • Samsara BioCapital's ten largest holdings make up 76% of its $646M portfolio in Q1 2024.
  • Samsara BioCapital opened 2 new positions and closed 4 in Q1 2024.
  • Samsara BioCapital's portfolio value rose 0.56% quarter-over-quarter to $646M.

Based on Samsara BioCapital's 13F filing for Q1 2024, filed 15 May 2024.